gp100 (178-187)
TECHNICAL SPECIFICATIONS
| Item | Specification |
|---|---|
| Product Name | gp100 (178-187) (Melanocyte Protein PMEL 17 (178-187) peptide |
| CAS NO. | / |
| Appearance | White to off-white lyophilized powder |
| Molecular Formula | C42H71N11O14S2 |
| Molecular Weight | 1018.23g/mol |
| Purity (RP-HPLC) | ≥ 95.0% |
| Solubility | Soluble in water (≥ 5 mg/mL), dilute acetic acid (0.1% v/v), DMSO, and phosphate-buffered saline |
| Endotoxin | ≤1.0 EU/mg |
| Biological Activity | HLA-A2-restricted CD8⁺ cytotoxic T-lymphocyte (CTL) epitope. |
| Storage Conditions | Store at -20°C to -80°C in a dry, dark, desiccated environment. |
| Stock Location | Stock in USA |
| MOQ | 1g |
1.MECHANISM OF ACTION
This peptide acts as a specific antigen for cytotoxic T lymphocytes (CTLs) within the framework of anti-tumor immunity. In melanoma cells, the full-length gp100 protein is processed intracellularly, and this specific 10-mer fragment is presented on the cell surface bound to the HLA-A0201 molecule. As an exogenous peptide, it can be loaded onto HLA-A0201 on professional antigen-presenting cells (APCs) in vitro. The gp100 (178-187)/HLA-A0201 complex is specifically recognized by complementary T-cell receptors on CD8+ T cells.
- Melanoma-Specific T-Cell Research: Investigating the frequency, phenotype, and functionality of gp100 (178-187)-reactive T cells in melanoma patients or healthy donors.
- In VitroT-Cell Stimulation & Expansion: Generating and expanding antigen-specific human CTL lines or clones from HLA-A*0201+ donor PBMCs for use in cytotoxicity assays and functional studies.
- Immune Monitoring: Serving as the target antigen in sensitive immune assays such as enzyme-linked immunospot (ELISPOT) for IFN-γ, intracellular cytokine staining (ICS) by flow cytometry, or HLA tetramer staining to track antigen-specific T-cell responses in clinical trial samples or preclinical models.
2.PRODUCT INDICATIONS
- Preclinical Validation: This epitope has been validated in numerous in vitroand animal studies as capable of eliciting strong, tumor-specific CTL responses, establishing its relevance as a melanoma-associated antigen.
- Clinical Trial Context: Alongside other gp100 epitopes (like 154-162 and 209-217), the 178-187 peptide has been incorporated into various cancer vaccine clinical trials for metastatic melanoma, often in combination with immune adjuvants or cytokines like IL-2.
- Therapeutic Modality: While peptide vaccine trials have shown limited objective response rates as monotherapies, this epitope remains a prime target for more potent adoptive T-cell therapy (ACT). In ACT, T-cells are engineered with TCRs recognizing this epitope, leading to demonstrated tumor regression in some patients in clinical studies.
3.CLINICAL EFFICACY OF PRODUCT
4.DELIVERY & SHIPPING
We specialize in global logistics for various cosmetic peptides. Your order will be handled with the utmost care, ensuring safe, reliable, and intact delivery.
Professional and Secure Packaging
Each bottle of peptide is protected with a special packaging solution to ensure stability and integrity during transportation.
We can also customize packaging according to customer needs.
Shipping Methods
Main Method: International Air Freight
We primarily use DHL, FedEx, UPS, and TNT because of their global reliability, speed, and advanced tracking systems. Air freight ensures the fastest transit time and minimizes the impact of environmental factors on the product.
